Get the Stockscreener App
12.19
2.25%
-0.28
Eyepoint Inc stock is traded at $12.19, with a volume of 1.47M.
It is down -2.25% in the last 24 hours and down -15.35% over the past month.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$12.47
Open:
$12.45
24h Volume:
1.47M
Relative Volume:
1.23
Market Cap:
$1.02B
Revenue:
$7.62M
Net Income/Loss:
$-271.60M
P/E Ratio:
-3.4811
EPS:
-3.5018
Net Cash Flow:
$-271.54M
1W Performance:
-8.35%
1M Performance:
-15.35%
6M Performance:
-19.70%
1Y Performance:
+16.21%
1-Day Range:
$12.06
$12.50
1-Week Range:
$12.06
$13.79
52-Week Range:
$9.40
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
12.19 | 1.02B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
EYPT|EyePoint Pharmaceuticals Inc|Price:12.190|Chg%:-0.280 - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence - TradingKey
RBC Capital Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $37 - Moomoo
J.P. Morgan Maintains EyePoint(EYPT.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
EYPT (NASDAQ: EYPT) plans sale of 1,235 common shares from options - Stock Titan
EYPT (NASDAQ: EYPT) affiliate plans sale of 1,235 common shares via Form 144 - Stock Titan
Form 144 EyePoint For: 21 July By Investing.com - Investing.com Nigeria
EYPT (NASDAQ: EYPT) plans brokered sale of 421,235 shares valued at $5.5M - Stock Titan
Price to earnings forward of EyePoint, Inc. – MUN:PV3B - TradingView
Drug company to pay $4.7M after admitting it paid providers to use its product - Yahoo Finance
Watertown Company Will Pay Nearly $4.7 Million to Resolve False Claims Act Allegations - watertownmanews.com
EyePoint Pharmaceuticals Agrees to Pay $4.6 Million to Settle False Claims Act Allegations - Markets Herald
EyePoint, Inc. Settles DOJ False Claims Act Case and Implements Comprehensive Compliance Program - Minichart
Price-Driven Insight from (EYPT) for Rule-Based Strategy - Stock Traders Daily
EyePoint Pharmaceuticals Agrees to Settle US False Claims Act Allegations - Moomoo
EyePoint to Pay $4.7M to Resolve Allegations of False Claims Act Violations - Moomoo
Eyepoint Enters Settlement Agreement With DOJ, OIG-HHS, And DHASEC Filing - TradingView
EyePoint Pharmaceuticals (EYPT) Settles for $4.6M Over Kickback Allegations - GuruFocus
EyePoint (NASDAQ: EYPT) signs five-year federal Corporate Integrity Agreement - Stock Titan
United States: EyePoint Pharmaceuticals To Pay $4.6 Million To Resolve False Claims Act Allegations - The St Kitts Nevis Observer
EyePoint Agrees To Pay $4.65M To U.S. Government In FCA Suit Settlement - Mealey's
EyePoint to pay $4.6M to settle with DoJ over kickback claims - Seeking Alpha
Stifel Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $40 - Moomoo
EYPT Initiated Coverage by Stifel -- Buy Rating with $40 Price T - GuruFocus
This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Two New EyePoint Employees Receive Options for 63,500 Shares - Stock Titan
Stifel initiates EyePoint stock with buy rating on retinal drug potential By Investing.com - Investing.com South Africa
Stifel initiates EyePoint stock with buy rating on retinal drug potential - Investing.com Nigeria
Stifel Initiates EyePoint(EYPT.US) With Buy Rating, Announces Target Price $40 - Moomoo
EyePoint, Inc. (EYPT) CEO exercises RSUs, with shares withheld for taxes - Stock Titan
Mizuho Securities Remains a Buy on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
EyePoint Names Tarek S. Hassan, MD, as SVP and Chief Strategic Science Officer - VisionMonday.com
Mizuho Securities Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
EyePoint Appoints Retina Specialist Tarek S. Hassan as Chief Strategic Science Officer - citybiz
EyePoint Appoints Retina Specialist Dr. Tarek S. Hassan as Chief Strategic Science Officer - Quiver Quantitative
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer - marketscreener.com
Renowned retina specialist Tarek S. Hassan joins EyePoint ahead of key DURAVYU trial readout - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Does EyePoint’s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU‑Centric Investor Base? - simplywall.st
ETFs Investing in EyePoint, Inc. Stocks - TradingView
EyePoint Pharmaceuticals updates its strategy as retinal pipeline advances - AD HOC NEWS
EyePoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight - Moomoo
EYPT Assumed by Cantor Fitzgerald -- Rating Overweight with PT a - GuruFocus
Price to sales forward of EyePoint, Inc. – FWB:PV3B - TradingView
Here’s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks - Yahoo Finance
EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901 - Ophthalmology Times Europe
JonesTrading Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Price to sales forward of EyePoint, Inc. – DUS:PV3B - TradingView
Price to earnings forward of EyePoint, Inc. – DUS:PV3B - TradingView
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):